LABP News and Press, Landos Biopharma Inc. From 08/21/23

2023-08-21 11:52:45 ET More on Health Care Select Sector SPDR XLV Vs. VHT: A Head-To-Head Healthcare ETF Comparison XLV: The Powerhouse ETF Driving Health And Wealth BlackRock spotlights healthcare as an opportunity with recession talks in the air Goldman add...

2023-08-10 14:20:32 ET Landos Biopharma press release ( NASDAQ: LABP ): Q2 GAAP EPS of -$0.63. the Company had cash, cash equivalents and marketable securities of $44.7 million, For further details see: Landos Biopharma GAAP EPS of -$0.63

Initiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis NEXUS Remains On Track With Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NA...

2023-07-05 08:14:54 ET Amneal Pharmaceuticals ( AMRX ) -13% . Advanced Health Intelligence ( AHI ) -10% . Landos Biopharma ( LABP ) -10% . InterCure ( INCR ) -9% . Alliance Entertainment Holding Corporation ( AENT ) -9% . Renalyt...

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will participate at the Jefferies Healthcare Conference, to be held from Jun...

NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee...

2023-05-25 16:35:35 ET Landos Biopharma ( NASDAQ: LABP ) will implement a 1-for-10 reverse stock split of its outstanding shares of common stock, effective on May 25. The Company's common stock will trade on a split-adjusted basis starting May 26, under the same trading symbol...

NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock ...

2023-05-12 09:04:34 ET Landos Biopharma press release ( NASDAQ: LABP ): Q1 GAAP EPS of -$0.09 beats by $0.01 . Cash, cash equivalents and marketable securities were $50.0 million as of March 31, 2023, as compared to $44.4 million on December 31, 2022. The Company e...

NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical...